enokizumab   Click here for help

GtoPdb Ligand ID: 8934

Synonyms: 7F3com-2H2 | MEDI-528 | MEDI528
Immunopharmacology Ligand
Compound class: Antibody
Comment: Enokizumab is a humanized monoclonal antibody targeting interleukin 9 (IL-9), being investigated for its immunomodulatory potential.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide searches using the variable regions of the heavy and light chains of the antibody reveal exact matches with sequences submitted with patent US7354584 [5], which correspond to antibody construct 7F3com-2H2 therein..
No information available.
Summary of Clinical Use Click here for help
Enokizumab has been evaluated in Phase II clinical trials as a potential anti-asthmatic therapy [2,4]. Click here to link to ClinicalTrials.gov's full listing of Phase II enokizumab (research coded MEDI528 or MEDI0528) trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Preclinical studies suggest that IL-9 is a potential key mediator in the development and maintenance of airway inflammation in asthma. Anti-IL-9 therapy is considered to address the unmet need for controlling disease in patients unresponsive to current treatment strategies. The role of the IL-9-mast cell axis in asthma is reviewed in [3].